These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36366295)

  • 1. Utility of IL-6 in the Diagnosis, Treatment and Prognosis of COVID-19 Patients: A Longitudinal Study.
    Jain V; Kumar P; Panda PK; Suresh M; Kaushal K; Mirza AA; Raina R; Saha S; Omar BJ; Subbiah V
    Vaccines (Basel); 2022 Oct; 10(11):. PubMed ID: 36366295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The intercorrelations between blood levels of ferritin, sCD163, and IL-18 in COVID-19 patients and their association to prognosis.
    Volfovitch Y; Tsur AM; Gurevitch M; Novick D; Rabinowitz R; Mandel M; Achiron A; Rubinstein M; Shoenfeld Y; Amital H
    Immunol Res; 2022 Dec; 70(6):817-828. PubMed ID: 36222965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
    Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
    J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation During Acute Respiratory Distress: A Case Report and Literature Review.
    Farooqi F; Dhawan N; Morgan R; Dinh J; Nedd K; Yatzkan G
    Trop Med Infect Dis; 2020 Jul; 5(3):. PubMed ID: 32635353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India.
    Gokhale Y; Mehta R; Kulkarni U; Karnik N; Gokhale S; Sundar U; Chavan S; Kor A; Thakur S; Trivedi T; Kumar N; Baveja S; Wadal A; Kolte S; Deolankar A; Pednekar S; Kalekar L; Padiyar R; Londhe C; Darole P; Pol S; Gokhe SB; Padwal N; Pandey D; Yadav D; Joshi A; Badgujar H; Trivedi M; Shah P; Bhavsar P
    BMC Infect Dis; 2021 Mar; 21(1):241. PubMed ID: 33673818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of serum SARS-CoV-2 IgM and IgG serology and clinical outcomes in COVID-19 patients: Experience from a tertiary care centre.
    Suresh M; Kumar P; Panda PK; Jain V; Raina R; Saha S; Vivekanandhan S; Omar BJ
    World J Biol Chem; 2023 Mar; 14(2):52-61. PubMed ID: 37034133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of interleukin-18 and its association with other inflammatory markers and disease severity in COVID-19.
    Satış H; Özger HS; Aysert Yıldız P; Hızel K; Gulbahar Ö; Erbaş G; Aygencel G; Guzel Tunccan O; Öztürk MA; Dizbay M; Tufan A
    Cytokine; 2021 Jan; 137():155302. PubMed ID: 33002740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the Impact of Inflammatory Markers and CT Severity Score on Disease Severity of COVID-19 Patients Admitted to ICU at a Tertiary Hospital.
    Kurri N; Tyagi B; Singhal E; Gupta N; Agarwal AK; Gupta V; Rai G; Bindra MS
    J Assoc Physicians India; 2021 Jun; 69(6):11-12. PubMed ID: 34472783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical Illness Due to Covid-19: A Description of the Surge in a Single Center in Sioux Falls.
    Jamous F; Meyer N; Buus D; Ateeli H; Taggart K; Hanson T; Alzoubaidi M; Nazir J; Devasahayam J
    S D Med; 2020 Jul; 73(7):312-317. PubMed ID: 32805781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent lymphocyte reduction and interleukin-6 levels are independently associated with death in patients with COVID-19.
    Xu Y; Wang N; Shen X; Liu X; Liu H; Liu Y
    Clin Exp Med; 2023 Nov; 23(7):3719-3728. PubMed ID: 37310657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukine-6 in critically ill COVID-19 patients: A retrospective analysis.
    Gorham J; Moreau A; Corazza F; Peluso L; Ponthieux F; Talamonti M; Izzi A; Nagant C; Ndieugnou Djangang N; Garufi A; Creteur J; Taccone FS
    PLoS One; 2020; 15(12):e0244628. PubMed ID: 33382773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective Cohort Observational Study to compare the Effect of Mycobacterium w along with Standard of Care vs Standard of Care alone in critically ill COVID-19 Patients.
    Dixit S; Zirpe K; Suryawanshi P; Borawake K; Prasad S; Ambapkar S; Ambapkar S; Joshi A; Joshi M
    J Assoc Physicians India; 2022 Jul; 70(7):11-12. PubMed ID: 35833395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
    Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
    Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictions based on inflammatory cytokine profiling of Egyptian COVID-19 with 2 potential therapeutic effects of certain marine-derived compounds.
    Elnosary ME; Shreadah MA; Ashour ML; Nabil-Adam A
    Int Immunopharmacol; 2024 Jan; 126():111072. PubMed ID: 38006751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basic Predictive Risk Factors for Cytokine Storms in COVID-19 Patients.
    Shcherbak SG; Anisenkova AY; Mosenko SV; Glotov OS; Chernov AN; Apalko SV; Urazov SP; Garbuzov EY; Khobotnikov DN; Klitsenko OA; Minina EM; Asaulenko ZP
    Front Immunol; 2021; 12():745515. PubMed ID: 34858403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits of early aggressive immunomodulatory therapy (tocilizumab and methylprednisolone) in COVID-19: Single center cohort study of 685 patients.
    Luis BM; Miguel MB; Pedro DL; David IP; Itziar A; Ana GH; Enrique IJ; María LV; Noelia TF; Julio César BB; Marta UI; Rodrigo SL; María CB; Andrés LM; Javier MI; Juan Pablo GM; Gerardo HF; Carolina NF; Jorge BL; María FR; Fernando CT; Sergio OE; Lourdes FC; María GE; Gregoria ML; Adolfo SR; José Antonio FR;
    J Transl Autoimmun; 2021; 4():100086. PubMed ID: 33615209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal changes of inflammatory parameters and their correlation with disease severity and outcomes in patients with COVID-19 from Wuhan, China.
    Zeng Z; Yu H; Chen H; Qi W; Chen L; Chen G; Yan W; Chen T; Ning Q; Han M; Wu D
    Crit Care; 2020 Aug; 24(1):525. PubMed ID: 32854750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colchicine anti-inflammatory therapy for non-intensive care unit hospitalized COVID-19 patients: results from a pilot open-label, randomized controlled clinical trial.
    Haroon MZ; Farooq U; Ashraf S; Zeb S; Gillani SY; Malik S; Ali R; Irshad R; Mehmood Z; Abbas Y; Masood A; Ghafoor A; Khalil AT; Asif H; Khan S; Ujjan ID; Nigar R; Livingstone S; Pascual-Figal DA; Togni S; Allergini P; Riva A; Khan A
    J Physiol Pharmacol; 2022 Jun; 73(3):. PubMed ID: 36302537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Inflammatory Markers With Disease Progression and the Severity of COVID-19.
    Patel SV; Pathak JM; Parikh RJ; Pandya KJ; Kothari PB; Patel A
    Cureus; 2024 Feb; 16(2):e54840. PubMed ID: 38533136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.